Immunome (IMNM) Revenue (2023 - 2025)

Immunome has reported Revenue for 3 years, with the latest figure at $4.0 million in Q2 2025.

• For the quarter ending Q2 2025, Revenue rose 69.84% year-over-year to $4.0 million; the trailing twelve-month figure through Mar 2026 stood at $4.0 million (down 63.29% YoY), and the FY2025 full-year result was $6.9 million, down 23.23% from the prior year.
• Revenue for Q2 2025 stood at $4.0 million, up from $2.9 million in the prior quarter.
• The five-year high for Revenue was $4.3 million in Q2 2023, with the low at $1.0 million in Q1 2024.
• Historically, Revenue has averaged $3.0 million across 3 years, with a median of $2.9 million in 2024.
• Annual changes were most pronounced in 2024 — Revenue sank 56.47% — and 2025, when it soared 184.35%.
• Immunome's Revenue stood at $3.8 million in 2023, then slipped by 28.44% to $2.7 million in 2024, then surged by 46.64% to $4.0 million in 2025.
• The last three Revenue figures came in at $4.0 million (Q2 2025), $2.9 million (Q1 2025), and $2.7 million (Q4 2024), per Business Quant data.